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Abstract
Anaplasma marginale is the most prevalent tick-borne livestock pathogen with worldwide
distribution. Bovine anaplasmosis is a significant threat to cattle industry. Anaplasmosis
outbreaks in endemic areas are prevented via vaccination with live A. centrale produced in
splenectomized calves. Since A. centrale live vaccine can carry other pathogens and cause
disease in adult cattle, research efforts are directed to develop safe recombinant subunit
vaccines. Previous work found that the subdominant proteins of A. marginale type IV secre-
tion system (T4SS) and the subdominant elongation factor-Tu (Ef-Tu) were involved in the
protective immunity against the experimental challenge in cattle immunized with the A.
marginale outer membrane (OM). This study evaluated the immunogenicity and protection
conferred by recombinant VirB9.1, VirB9.2, VirB10, VirB11, and Ef-Tu proteins cloned and
expressed in E. coli. Twenty steers were randomly clustered into four groups (G) of five
animals each. Cattle from G1 and G2 were immunized with a mixture of 50 μg of each
recombinant protein with Quil A® or Montanide™ adjuvants, respectively. Cattle from G3
and G4 (controls) were immunized with Quil A and Montanide adjuvants, respectively.
Cattle received four immunizations at three-week intervals and were challenged with 107 A.
marginale-parasitized erythrocytes 42 days after the fourth immunization. After challenge,
all cattle showed clinical signs, with a significant drop of packed cell volume and a significant
increase of parasitized erythrocytes (p<0.05), requiring treatment with oxytetracycline to
prevent death. The levels of IgG2 induced in the immunized groups did not correlate with
the observed lack of protection. Additional strategies are required to evaluate the role of
these proteins and their potential utility in the development of effective vaccines.
Introduction
Bovine anaplasmosis is an infectious disease caused by the obligate intraerythrocytic Gram-
negative bacterium Anaplasma marginale (order Rickettsiales; family Anaplasmataceae) [1],
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transmitted either biologically by ticks or mechanically by bloodsucking flies or through
blood-contaminated fomites. The disease is widely distributed in tropical and subtropical
regions of the world, and is in expansion due to the movement of cattle from endemic to non-
endemic areas [2,3]. Anaplasmosis, clinically characterized by anemia, hyperthermia, icterus,
weight loss, and reduced milk production, can produce 50% mortality in cattle older than 2
years of age that have not received specific treatment [1,4]. Cattle that overcome the acute
infection remain persistently infected for life and become a reservoir for A. marginale trans-
mission [1,5].
In some countries, the disease is currently prevented by the administration of a live vaccine,
based on the naturally less pathogenic A. marginale subsp. centrale (hereafter A. centrale),
amplified in splenectomized calves [1]. Some drawbacks of the live A. centrale vaccine include
the risk of transmission of other pathogens [6], the administration only to calves up to 10
months of age, and the achievement of partial protection against antigenically diverse A.
marginale strains [1,7,8].
Immunization of cattle with the native purified outer membrane (OM) of A. marginale has
induced complete protection against infection and clinical disease [4,9,10]. Such protection
was correlated with induction of high titers of IgG2 opsonizing antibodies against A. marginale
surface epitopes and macrophage activation mediated by CD4+ T cells [4,11]. The capacity of
OM native proteins to induce protection has promoted their consideration as vaccine candi-
dates [12,13]. However, this immunogen has been used only experimentally due to difficulties
in scaling up and standardization [14].
Antibody response in OM-vaccinated cattle is primarily directed against several immuno-
dominant major surface proteins (MSPs); however, these proteins failed to provide consistent
and complete protective immunity when used individually [15–17]. Complete genome
sequencing and proteomic studies of A. marginale allowed the identification of subdominant
proteins, which are present in low abundance on the OM [13]. These proteins remain invari-
ant during infection and are highly conserved among different strains, making them attractive
potential candidates for vaccines [12,18]. Subdominant proteins of A. marginale type IV secre-
tion system (T4SS), a 1.05-MDa complex that spans the outer and inner bacterial membranes
involved in the host cell adhesion/invasion, and the subdominant elongation factor-Tu (Ef-
Tu), a membrane-associated protein belonging to the family of hydrolases involved in protein
synthesis, are targets for neutralizing antibodies [12,19,20]. The T4SS proteins VirB9.1,
VirB9.2, VirB10, and VirB11 and the Ef-Tu have been recognized by sera from cattle immu-
nized with OM that withstood the challenge with a virulent strain of A. marginale [12,21,22].
In the present study, the immune protection against A. marginale induced by a vaccine
based on the recombinant proteins VirB9.1, VirB9.2, VirB10, VirB9.1, and Ef-Tu was evalu-
ated in cattle.
Material and methods
Cattle
The cattle involved in this research were born and raised in an anaplasmosis-free Holstein
dairy herd in Rafaela (31˚12’S-61˚30’W), a zone free from the cattle tick Rhipicephalus micro-
plus in Argentina. The study group included a 4-month-old splenectomized calf used to
amplify A. marginale and 20 2-year-old healthy steers used for vaccine evaluation, which were
maintained in different isolation pens. All cattle received forage, concentrate and drinking
water ad libitum. They were sprayed weekly with flumethrin (Bayticol1 Pour-On, Bayer) to
protect them from biting flies. All the animals were confirmed to be free of Anaplasma spp.
infection by cELISA and nested PCR (nPCR) before the start of the experiment [23,24]. All
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procedures were approved by the Animal Care Committee of the Faculty of Veterinary Sci-
ences, National University of Litoral (Protocol number 243/15).
Genomic DNA
DNA was purified from 900 μL of A. marginale-infected blood [25]. Briefly, erythrocytes were
lysed with erythrocyte lysis buffer (0.14 M NH4Cl, 0.17 M Tris—HCl) and the hemoglobin was
eliminated by washes with distilled water. The inclusion bodies were lysed in 400 μL of cellular
lysis buffer (0.05 M Tris—HCl, 0.1 M EDTA, 0.1 M NaCl, 2% SDS, pH 8) with 160 μg of pro-
teinase K. DNA was extracted with phenol/chloroform/isoamyl alcohol, precipitated with
isopropyl alcohol and washed with 75% ice-cold ethanol. The pellet was suspended in 50 μL
distilled water and kept at -20˚C until use. The concentration and purity of DNA was assessed
at 260–280 nm (NanoDrop 2000, Thermo Fisher Scientific, USA).
In silico analysis of proteins sequences
The prediction algorithm SignaIP 5.0 (http://www.cbs.dtu.dk/services/SignalP/) was used to
predict signal peptides [26]. TMpred algorithm was used to predict the transmembrane
domains of each protein (http://embnet.vital-it.ch/software/TMPRED_form.html) [27]. Solu-
bility of the full-length and truncated form (without transmembrane domains) of the proteins
was calculated using a prediction model based on overexpression of heterologous proteins in
E. coli (http://www.biotech.ou.edu/) [28].
Cloning of DNA sequences
The recombinant proteins VirB9.1 and VirB9.2 were cloned and expressed as truncated form,
without the signal peptide (tVirB9.1 and tVirB9.2). cDNA encoding residues 22–272 of
VirB9.1 (AAV86251.1), 27–281 of VirB9.2 (AAV87107.1) and full-length sequences of VirB10
(AAV87106.1), VirB11(RCL20095.1), and Ef-Tu (WP_037348707.1) proteins were amplified
by PCR using specific primers designed ad hoc (Table 1). The sequence for a six histidine tag
(6 His-tag) at the C-terminus of tVirB9.2, VirB10, VirB11, and Ef-Tu proteins was added to
the reverse primers (Table 1). Amplicons were cloned into pGEM-T Easy vector (Promega,
USA) according to the manufacturer’s instructions. E. coli JM 109 competent cells (Promega)
were transformed with the recombinant plasmids. Subsequently, a fragment was excised with
restriction enzymes NdeI and BamHI (sites shown in Table 1), and subcloned into pET9b
(Novagen, USA) to yield the ptVirB9.1, ptVirB9.2, pVirB10, pVirB11, and pEf-Tu plasmids.
The identity of the DNA constructs was confirmed by sequencing (Biotechnology Institute,
INTA CICVyA, Argentina). The constructs were used to transform E. coli BL21 RIL (DE3)
pLysS competent cells (Novagen).
Table 1. Primers designed ad hoc for amplifying the DNA sequences of tVirB9.1, tVirB9.2, VirB10, VirB11, and Ef-Tu proteins from Anaplasma marginale.
Protein name Forward primer (5´ to 3´) Reverse primer (5´ to 3´)
tVirB9.1 catatgcaggaaccgcgctctatag ggatcctttaaacccacgtccccttctggatg
tVirB9.2 catatggtaagcggtggtg ggatcctcagtgatggtgatggtgatggcggccttcaattttaaaaagcaccg
VirB11 catatgacagcaggatacgcagcgttag ggatccctagtgatggtgatggtgatgtttaaaatcattgccttgtgaacatttagtg
VirB10 catatgtcagacgaaaccaaggataataac ggatccctagtgatggtgatggtgatgtttaaacctacgcaccgcctccc
Ef-Tu catatgacagaagggagaaagcc ggatccctagtgatggtgatggtgatgtttaaactccaaaatctcagttatg
Sites of the restriction enzymes NdeI and BamHI are underlined. The sequences that codify for the six-histidine tag are shown in italics.
https://doi.org/10.1371/journal.pone.0229301.t001
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Protein expression and purification
E. coli BL21 RIL (DE3) pLysS competent cells carrying the plasmids ptVirB9.1, ptVirB9.2,
pVirB10, pVirB11, or pEf-Tu were cultured at 37 ˚C in 500 mL of Luria–Bertani medium,
supplemented with 50 μg/mL kanamycin and 34 μg/mL chloramphenicol to OD600nm = 1.
Protein expression was induced with 1% lactose for 3 h; then, E. coli cells were harvested by
centrifugation. The cells expressing tVirB9.2, VirB10, VirB11, and Ef-Tu proteins were sus-
pended in 10 mL of lysis buffer A (50 mM sodium phosphate, 300 mM NaCl, 10 mM imidaz-
ole, pH 8) and those expressing tVirB9.1 were suspended in 10 mL of lysis buffer B (50 mM
sodium phosphate, pH 7.2), both containing 1:1000 protease inhibitor cocktail set III (Cal-
biochem, USA). Finally, the cells were lysed twice at 20,000 psi using a cell disruptor (Aves-
tin Emulsiflex B15, Canada). Soluble and insoluble fractions were isolated by centrifugation
(12,000 xg, 4˚C, 30 min).
The tVirB9.1 and Ef-Tu proteins were purified from the soluble fraction of the E. coli lysate.
The soluble fraction of tVirB9.1 was precipitated by adding saturated ammonium sulfate up to
30% saturation with stirring for 20 min on ice. The precipitated protein was separated from
the supernatant by centrifugation (12,000 xg, 4 ˚C, 20 min). After desalting by dialysis in buffer
C (25 mM Tris–HCl, pH 7.2), tVirB9.1 was purified by ionic exchange chromatography on Q-
sepharose fast flow resin (GE Healthcare, USA) equilibrated with the same buffer. The resin
was washed with five volumes of buffer C containing 50 mM NaCl; then, the protein was
eluted with five volumes of buffer C containing 200 mM NaCl. The soluble fraction of Ef-Tu
was added to 2 mL of Ni+2-NTA agarose (Qiagen, Germany) previously equilibrated with lysis
buffer A. After incubation at 4 ˚C for 1 h, the suspension was poured into a 1.5 cm x 5.0 cm
column and washed with five volumes of 30 mM imidazole lysis buffer A. The protein was
eluted successively with five volumes of 100 mM and then with five volumes of 200 mM imid-
azole lysis buffer A.
The proteins tVirB9.2, VirB10, and VirB11 were purified under denaturing conditions.
The inclusion bodies were obtained from the insoluble fraction of the E. coli lysate and washed
three times using successively 1% of triton X-100, 2% of triton X-100 and 2 M urea, each
diluted in the wash buffer (50 mM Tris–HCl, 5 mM EDTA, 5 mM DTT, pH 8) and twice with
ultrapure water. All washes were performed by centrifugation at 12,000 xg, at 20 ˚C for 15 min.
The isolated inclusion bodies were solubilized by incubation at 25 ˚C for 3 h in denaturing
buffer D (100 mM sodium phosphate, 8 M urea, 5 mM β-mercaptoetanol, pH 8) for VirB10
and VirB11. The denaturing buffer E (100 mM sodium phosphate, 6 M guanidinium chloride,
5 mM β-mercaptoethanol, pH 8) was used to solubilize tVirB9.2. After centrifugation (12,000
xg, 20 ˚C, 30 min), the soluble fraction was added to 2 mL of Ni+2-NTA agarose previously
equilibrated with the corresponding denaturing buffer. After incubation at 20 ˚C for 1 h, the
suspension was poured into a column and washed with five volumes of 30 mM imidazole
denaturing buffer D. The proteins were eluted with five volumes of 200 mM imidazole
denaturing buffer D.
The purity of the proteins was assessed by sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) using a standard protocol [29]. The molar concentration in pure
samples was calculated by absorbance at 280 nm using the molar extinction coefficient (ε280
nm) of each protein (25600 M
-1cm-1, 26360 M-1cm-1, 11710 M-1cm-1, 25900 M-1cm-1, and
26025 M- 1cm-1 to tVirB9.1, tVirB9.2, VirB10, VirB11, and Ef-Tu, respectively).
Pure recombinant proteins were analyzed by Western blot (WB). Proteins were electropho-
resed (0.2 μg/lane) on a 12% SDS-PAGE and transferred to a nitrocellulose membrane (Trans-
Blot1 0.45 μm, Bio-Rad), by electroblotting at 50 V for 2 h. The membrane was blocked in
TBS (50 mM Tris–HCl, 150 mM NaCl, pH 7.6)/5% nonfat dried milk overnight at 4 ˚C. After
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five washes with TBST (TBS/0.05% Tween-20), it was incubated with mouse anti-His-tag
MoAb (MA1-21315, Thermo Fisher Scientific), diluted 1:2000 in TBST/10% nonfat dried milk
at room temperature for 1 h. After five washes with TBST, it was incubated with goat anti-
mouse IgG peroxidase conjugate (#115-036-072 Jackson ImmunoResearch Inc., USA) at the
same dilution for 1 h. The reaction was revealed by adding the colorimetric substrate 3,3’-dia-
minobenzidine tetrahydrochloride (DAB) (Sigma-Aldrich, USA).
Three proteins, major surface protein 5 (MSP5) of A. marginale, surface antigen 1 (SAG1)
of Neospora caninum, and merozoite surface antigen 2c (MSA2c) of Babesia bovis were
expressed in E. coli and purified by pseudo-affinity on a Ni+2-NTA agarose column following
the protocol descripted for MSP5 protein [30]. These proteins share the sequence (FKIEGRH
HHHHH) in the C-terminal extreme with four of the proteins used as immunogens, and were
used for the anti-His-tag adsorption step or for the determination of the presence of these anti-
bodies at the post-absorption step.
Immunization
Two vaccine formulations based on a mixture of 50 μg of each pure recombinant protein
(tVirB9.1, tVirB9.2, VirB10, VirB11, and Ef-Tu) diluted in PBS were adjuvanted with 1 mg/
mL Quil A (Brenntag, Denmark) or 50% v/v Montanide ISA201 (Seppic Inc., France). Quil-A
formulations were prepared by adding the solid compound into diluted proteins. Montanide
formulations were prepared following Seppic’s indications. Briefly, a stable emulsion W/O/W
was prepared in a one-step process using a low shear rate and controlled temperature at 31˚C
(+/-1 ˚C).
Twenty steers were randomly clustered into four groups (G) of five animals each (n = 5)
and immunized with the recombinant proteins/Quil A (G1) or recombinant proteins/Monta-
nide (G2) and PBS/Quil A (G3) or PBS/Montanide (G4), as controls. Cattle received four
doses of 2 mL of the corresponding immunogen by subcutaneous (SC) injection in the neck,
at three-week intervals (days 0, 21, 42, and 63). The presence of swelling at the immunization
site was recorded. The cattle were bled once before immunization and then weekly during 10
weeks; the serum samples were stored at -20 ˚C until use.
Challenge
An isolate of A. marginale from Salta (Argentina) that had been stored frozen was used to
challenge the immunity of the cattle [31]. Cryopreserved parasitized blood was thawed and
inoculated into a splenectomized calf [32] that was bled when the parasitemia reached 5%,
in 5% sodium citrate as anticoagulant. Each challenge dose was adjusted to 107 parasitized
erythrocytes in a 2-mL final volume and inoculated SC to the cattle, on day 42 after the
fourth immunization. The clinical reaction was monitored daily during 40 days, starting 10
days post-challenge (dpch), by measuring body temperature (T) in degrees Celsius (˚C),
packed cell volume (PCV), and percentage of parasitized erythrocytes (PPE) through blood
smears stained with Giemsa that were microscopically analyzed (1000x) [33]. Cattle were
treated with 20 mg kg-1 oxytetracycline (Terramicina1 LA, Pfizer) to prevent death when
the clinical parameters achieved �15 PCV, �5 PPE, or when the T was�41 ˚C during
three consecutive days. The clinical parameters of each group were expressed as the mean
of the maximum percent (%) drop of PCV, mean of the maximum PPE and mean of the
cumulative T above 39.5 ˚C. Cattle were bled weekly during five weeks after challenge;
the whole blood was analyzed by nPCR and the serum samples were tested by cELISA
[23,24].
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Antibody response
An indirect ELISA (iELISA) was used to detect total IgG (IgGT), IgG1, and IgG2 specific
against tVirB9.1, tVirB9.2, VirB10, VirB11, and Ef-Tu. To eliminate antibodies directed
toward remnant E. coli proteins and the C-terminal His-tag, sera from immunized cattle were
adsorbed with lysate from E. coli expressing SAG1. To evaluate the removal of anti-His-tag
antibodies from immune sera, IgGT against A. marginale MSP5 and Babesia bovis MSA2c
were measured. Optimal dilutions were established using checkerboard titrations with dilu-
tions of sera, antigens and conjugates [34]. Polystyrene microplates (Thermo Fisher Scientific)
were individually coated with 100 μL of each recombinant protein (5 μg/mL) in PBS (145 mM
NaCl, 4.4 mM NaHPO4, 18.3 mM NaH2PO4), and incubated overnight at 4 ˚C. The coated
plates were washed with PBS three times and incubated with 300 μL of blocking buffer (PBS/
10% nonfat dried milk) at 25 ˚C for 1 h. These conditions were also used for sera and conjugate
incubations.
To assess IgGT, the plates were washed with PBST (PBS/0.05% Tween-20) three times and
then incubated with 100 μL of serum samples diluted 1:10 in PBST/10% nonfat dried milk.
After four washes with PBST, they were incubated with 100 μL of rabbit anti-bovine IgG
peroxidase conjugate (A5295, Sigma-Aldrich), diluted 1:2000 in PBST/10% nonfat dried milk.
After four washes as above, 100 μL of chromogenic substrate 1 mM 2,2’-Azinobis [3-ethylben-
zothiazoline-6-sulfonic acid]-diammonium salt (ABTS) (Sigma-Aldrich) in 0.05 M sodium
citrate pH 4.5, 0.03% v/v H2O2 was added. The absorbance was measured in a microplate
reader at 405 nm at 25 ˚C, 15 min after the addition of chromogenic substrate. The cutoff
point for each antigen was set as the OD405nm mean for the pre-immune sera (n = 20) + 3
standard deviation (SD) [35].
To assess IgG1 and IgG2 antibodies, the ELISA protocol described above was performed
with a few modifications. Serum samples were diluted 1:20 and the mouse anti-bovine IgG1
MoAb (MCA627 Serotec™, UK) or IgG2 (B8400, Sigma-Aldrich) were added at a dilution of
1:1000. As second antibody, goat anti-mouse IgG peroxidase conjugate (Jackson, ImmunoRe-
search) at the same dilution was used. The IgG1/IgG2 ratio of OD405nm was analyzed for G1
and G2 [36]. All field serum samples and controls were assayed in duplicate.
Specificity of antibodies
Anti tVirB9.1, tVirB9.2, VirB10, VirB11, and Ef-Tu antibodies from sera of G1 and G2 cattle
were evaluated by WB 7 days after the fourth immunization, following the previously described
protocol. Before the test, cattle sera were adsorbed by overnight incubation at 4 ˚C with an E.
coli lysate expressing SAG1. To evaluate the removal of anti-His-tag antibodies from immune
sera, MSP5 was included as a control in the WB.
The recognition of the proteins expressed in A. marginale by the cattle sera was evaluated
by WB using a crude antigen of A. marginale purified from blood of a splenectomized calf
with 80% of parasitemia. This A. marginale crude antigen was obtained following the protocol
described for production of antigen of Card agluttination test [8]. In the WB, sera were diluted
1:100. The antigen-antibody reaction was detected using rabbit anti-bovine IgG peroxidase
conjugate (A5295, Sigma-Aldrich) at a dilution of 1:1000.
Statistical analysis
Data were analyzed using the software InfoStat (Universidad Nacional de Co´rdoba, Co´rdoba,
Argentina) (http://www.infostat.com.ar). The levels of antibodies against recombinant pro-
teins were compared between groups using a Generalized Linear Model of repeated measure-
ments with Gamma distribution as a link function considering the frequency distribution of
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the response variable. The means of the clinical parameters, cumulative T above 39.5˚C, maxi-
mum % drop of PCV, and maximum PPE between groups after the challenge were compared
using ANOVA. Differences in the mean of antibodies anti-MSP5 (inhibition percentage)
between immunized and control groups on different dpch were analyzed by Mann Whitney
test. All statistical analyses were considered significant at p<0.05.
Results
Sequences analysis, expression and purification of recombinant proteins
In silico analysis showed that VirB9.1 and VirB9.2 proteins contain a signal peptide with a
cleavage site within the 20–21 and 25–26 residue region, respectively (S1 Table). No signal
peptides were identified for VirB10, VirB11, or Ef-Tu proteins. The analysis of the primary
structure of the proteins showed a transmembrane helix (TMH) in the N-terminus of VirB9.1
(residues 4–22) and VirB9.2 (residues 7–27) and two TMH in VirB10 (residues 29–47 and
339–357). TMH was not predicted in VirB11 or Ef-Tu. The predicted solubility for the pro-
teins VirB9.1, VirB9.2, and VirB10, which contain a hydrophobic region, was 38.7%, 100%,
and 0%, respectively. The solubility for VirB9.1 increased to 98.7% when it was expressed as
truncated protein (residues 22–272). Removal of the hydrophobic region did not modify the
predicted solubility for the VirB9.2 or VirB10 proteins. The VirB9.1 and VirB9.2 proteins
were expressed without their signal peptide, whereas VirB10, VirB11, and Ef-Tu proteins were
expressed with their full-length sequence. The recombinant proteins tVirB9.1 and Ef-Tu were
expressed in soluble form in the cytoplasm of E. coli with a yield of 20 and 15 mg per liter of
culture after their purification, respectively. The recombinant proteins tVirB9.2, VirB10, and
VirB11 were expressed mainly in inclusion bodies and had a yield of 20, 10, and 12 mg per
liter of culture, respectively, after their purification under denaturing conditions.
The approximate molecular masses for the purified tVirB9.1, tVirB9.2, VirB10, VirB11,
and Ef-Tu were 28, 29, 49, 38, and 44 kDa, respectively (Fig 1A). The molecular size observed
agrees with that expected for each protein. The recombinant proteins reacted with the MoAb
anti-His tag (Fig 1B), except for tVirB9.1, which lacked the His-tag epitope.
Adjuvant reaction
Cattle that received Montanide as adjuvant (G2 and G4) showed a small inflammatory reaction
<1.5 cm at the immunization site (neck region), whereas no reaction was observed in those
that received Quil A (G1 and G3).
Fig 1. Evaluation of Anaplasma marginale purified recombinant proteins. (A) SDS-PAGE, stained with Coomassie
Brilliant Blue R-250. (B) Western blot using anti-His-tag MoAb. MW: molecular weight marker (kDa); lane 1: VirB10;
lane 2: tVirB9.1; lane 3: VirB11; lane 4: tVirB9.2; lane 5: Ef-Tu.
https://doi.org/10.1371/journal.pone.0229301.g001
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Antibody response
All G1 and G2 cattle generated antibodies against each recombinant protein after immuniza-
tions, detected by iELISA, whereas G3 and G4 cattle remained negative until the challenge.
The kinetics of IgGT, IgG1, and IgG2 was similar for G1 and G2, both after immunizations
and after challenge with A. marginale. An increase of IgGT levels against tVirB9.1, tVirB9.2,
VirB10, VirB11, and Ef-Tu, above the cutoff point, was detected from day 7 after the second
immunization (Fig 2). From this day, G1 and G2 cattle showed similar IgGT levels (p>0.05)
(Fig 2). Regarding the immune response stimulated by each antigen individually, tVirB9.1 and
tVirB9.2 induced a higher level of IgGT than VirB10, VirB11, and Ef-Tu (p<0.05). At 35 dpch,
G3 and G4 cattle showed a significant increment of IgGT levels (p<0.05), although the values
were lower than those of G1 and G2 cattle. At this time, antibodies against A. marginale MSP5
protein were detected in the four groups of cattle (Fig 2).
tVirB9.1, tVirB9.2, VirB10, VirB11, and Ef-Tu but not MSP5 were recognized by antibodies
present in serum samples of all G1 and G2 cattle obtained 7 days after fourth immunization,
when they were evaluated by WB (Fig 3). Moreover, these antibodies recognized proteins in
the A. marginale crude antigen (Fig 3).
The recombinant proteins tVirB9.1, tVirB9.2, VirB10, VirB11, and Ef-Tu, using Quil A or
Montanide as adjuvants, induced a stronger IgG2 response than that of IgG1 both after immu-
nizations and after challenge (p<0.05), and the IgG1/IgG2 ratio remained <1 (Table 2). All
cattle from G3 and G4 showed an increase of IgG1 and IgG2 levels after challenge (p<0.05),
but with lower values than those reached by G1 and G2 cattle (Fig 2).
Response to challenge
After challenge with 107 erythrocytes parasitized with A. marginale, cattle from all groups
responded with a significant drop of PCV and a significant increase of PPE (p<0.05), requiring
treatment (20 mg kg-1 oxytetracycline) to prevent their death. After a prepatent period of 20 ± 1
days, A. marginale infection was confirmed through Giemsa stained blood smears in all cattle.
There were no significant differences between groups in the means of the evaluated clinical
parameters (p>0.05) (Table 3). The antibiotic treatment administered to cattle between days 23
and 30 after challenge attenuated the drop of PCV and the increase of PPE. The maximum %
drop of PCV and the maximum PPE were recorded between days 28 and 30 after challenge in
all cattle.
Infection was confirmed in all cattle by nPCR at 14 dpch. By cELISA and iELISA, all cattle
were positive at 35 dpch (Fig 2). At 14 dpch, the mean of anti-MSP5 antibodies, determined by
cELISA and expressed as percentage of inhibition, of the immunized groups was higher than
the mean of the control groups. These results show a greater number of positive immunized
animals (6/10) than that of positive controls animals (0/10).
Discussion
In this work, five subdominant A. marginale proteins were tested as immunogens in cattle.
These proteins were postulated as vaccine candidates, but have not been evaluated in an
immunization and challenge experiment [12,22]. Recombinant tVirB9.1, tVirB9.2, VirB10,
VirB11, and Ef-Tu proteins failed to induce protection against the pathogenic effects of A.
marginale following the experimental challenge.
The outer membrane (OM) T4SS proteins are important for intracellular survival and viru-
lence of Gram negative bacteria [12,37]. Many of those proteins are exposed on the cell surface,
where they could be targeted by neutralizing antibodies. The subdominant epitopes are eligible
to induce immune protection, as it was clearly established for other pathogens [38,39]. T4SS
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proteins and Ef-Tu are highly conserved among geographically distinct strains of A. marginale
[12].
Tebele et al. (1991) and Brown et al. (1998) demonstrated that immunization of calves with
fractions or the whole A. marginale OM, adjuvanted with saponin, induced immune protec-
tion against homologous challenge, characterized by a strong T helper cell immune response
Fig 2. Kinetics of antibody response (IgGT, IgG1, and IgG2) to each recombinant protein measured by iELISA. Group 1,
recombinant proteins/Quil A (—); Group 2, recombinant proteins/Montanide (---); Group 3, PBS/Quil A ( ) and Group 4, PBS/
Montanide ( ). Each point represents the mean ± SEM of the OD405nm at different days after immunization and at 35 days after
challenge (day 140). IgGT against A. marginale MSP5 and B. bovis MSA2c were measured as control of the presence of anti-His-tag
antibodies. The horizontal dotted line indicates the cutoff point. The arrows indicate the days of the immunizations and the vertical
dotted line indicates the day of challenge with A. marginale (on day 42 after the fourth immunization).
https://doi.org/10.1371/journal.pone.0229301.g002
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and high titers of IgG2 [4,9]. Despite the response of IgG2 observed in this work, both vaccine
formulations failed to mitigate the course of infection. Other subdominant proteins from the
OM, AM854 and AM936, were able to induce IgG2 immune response; however, they also
failed to protect against the challenge [40]. Albarrak et al. (2012) demonstrated that the sub-
dominant protein AM779 from the OM was unable to protect calves after the homologous
challenge with adult males of Dermacentor andersoni infected with the A. marginale St. Maries
strain [41]. In those experiments, IgG2 titers to subdominant proteins were similar in cattle
immunized with recombinant proteins or purified OM. This finding supports the theory that
antigen amount is not a primary determinant of subdominance for B cell responses [41]. The
IgG2 titers specific for subdominant proteins obtained from cattle vaccinated with OM ranged
from 100 to 5,000 [12,40,41], in contrast with IgG2 titers to MSP2, which were higher than
30,000 [12,41]. It is possible that the lack of protection in our work was due to low IgG2 levels;
however, it has been shown that IgG2 titers do not correlate with protection [41]. In addition,
the clinical signs observed in this work were similar to those reported for cattle immunized
with subdominant recombinant proteins [40,41].
The antibody response to MSP5 14 dpch was observed in 60% of immunized cattle (G1 and
G2), whereas control cattle (G3 and G4) remained negative. This difference could be attributed
to the presence of opsonizing antibodies generated after immunization with the recombinant
Fig 3. Reactivity of sera obtained 7 days after the fourth immunization from cattle inoculated with recombinant
proteins/Quil A (Group 1) or recombinant proteins/Montanide (Group 2) by Western blot. A representative steer
of group 1 is shown. MW: molecular weight marker (20, 25, 37, 50 kDa). Lane 1: MSP5; lane 2: Ef-Tu; lane 3: tVirB9.2;
lane 4: VirB11; lane 5: tVirB9.1; lane 6: VirB10; lane 7: A. marginale crude antigen. Sera were diluted 1/100 and the
reaction was detected with anti-bovine IgG peroxidase conjugate.
https://doi.org/10.1371/journal.pone.0229301.g003
Table 2. Mean of IgG1/IgG2 ratio (OD405nm) in the immunized groups recorded on day 7 after the fourth immunization with recombinant proteins/Quil A (Group
1) or recombinant proteins/Montanide (Group 2) and 35 days after challenge with Anaplasma marginale.
Groups Mean of IgG1/IgG2 ratio (Day 7 after the fourth immunization/Day 35 after-challenge)
tVirB9.1 tVirB9.2 VirB10 VirB11 Ef-Tu
Group 1 0.43/0.52 0.23/0.35� 0.25/0.40� 0.38/0.51� 0.43/0.56
Group 2 0.63/0.66 0.42/0.47 0.23/0.34 0.32/0.42 0.63/0.58
Significant differences (p<0.05) between pairs of values are indicated with an �
https://doi.org/10.1371/journal.pone.0229301.t002
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proteins. It is well known that antibodies are better opsonins for the adaptive immune system
than the complement factors of the innate immune system. Thus, after the challenge, in the
immunized cattle the antibodies directed against A. marginale surface exposed proteins
(VirB9.1, VirB9.2, and VirB10), opsonized the bacteria and were recognized, through the Fc
region of the IgG, by the phagocytic cells that processed the opsonized bacteria and presented
to T cells. This process would favor the early secretion of antibodies in the immunized
animals.
The lack of protective immunity observed in this study could be attributed to the failure of
the recombinant proteins to expose their critical epitopes with the correct conformation and
generate a protective immune response. The proper conformational structure of epitopes is
obtained when the recombinant proteins are expressed in native form [14,42], a task that is
difficult to perform with the OM proteins of A. marginale due to their intrinsic characteristics.
In previous works, recombinant VirB9.1, VirB9.2, VirB10, VirB11, and Ef-Tu proteins were
obtained under denaturing conditions [12,21,22]. Zhao et al. (2016) were able to express
VirB9.1 in the E. coli soluble fraction as GST-VirB9.1, whereas VirB9.2 expressed in the insolu-
ble fraction as SUMO-VirB9.2 was then refolded [14]. The cloning and expression of heterolo-
gous recombinant proteins in E. coli that lack the signal peptide can increase the expression
levels and the solubility of the proteins without affecting their immunogenicity [43]. In this
work, in silico analysis showed that the expression of soluble VirB9.1 was improved without
inclusion of the signal peptide; thus, tVirB9.1 (residues 22–272) was expressed in the E. coli
soluble fraction. Contrary to results reported by Zhao et al. (2016) [14], refolding of tVirB9.2
without its signal peptide (residues 27–281), obtained in the insoluble fraction in E. coli, was
not achieved. This difference could be explained by the use of the SUMO fusion protein,
which prevents aggregation of folding intermediates, keeping them in solution long enough to
adopt correct conformations [44].
Another cause of vaccine failure in this study may have been the inability of the immuno-
gen to generate antibodies that block the parasite entry to the host cell. The most successful
vaccines target highly conserved epitopes required by the pathogenic parasites for their host
cell entry [45]. During A. marginale multiplication, new antigenic variants of MSP2 are gener-
ated. Studies have demonstrated that this antigenic variation of MSP2 also occurs during per-
sistent A. centrale infections [46]. The conservation of CD4+ T-cell epitopes between A.
marginale-MSP2 and A. centrale-MSP2, and the generation of new antigenic variants during
the Anaplasma life cycle may contribute to the cross-protection produced by A. centrale live
vaccine. In addition, studies have shown that multi-antigen vaccines may be more effective to
induce a protective response than an individual antigen [47]. In this work, the five proteins
evaluated may have been insufficient to generate antibodies capable to block the erythrocytes
invasion by A. marginale.
Table 3. Mean values (± SD) of clinical parameters for each group of cattle immunized with four doses of recombinant proteins/Quil A (Group 1), recombinant
proteins/Montanide (Group 2), PBS/Quil A (Group 3), or PBS/Montanide (Group 4) after challenge with 107 Anaplasma marginale parasitized erythrocytes.
Groups Maximum percent drop of PCV Maximum PPE Cumulative T above 39.5 ˚C OTC-treated cattle (n/n)
Group 1 48.4 ± 5.1 5.8 ± 0.8 1.2 ± 0.5 5/5
Group 2 44.4 ± 3.9 6.0 ± 1.0 1.4 ± 0.8 5/5
Group 3 45.7 ± 7.7 6.9 ± 0.2 1.1 ± 0.6 5/5
Group 4 45.7 ± 7.9 7.0 ± 0.6 1.4 ± 0.8 5/5
PCV, packed cell volume; PPE, percentage of parasitized erythrocytes; T, body temperature; OTC, oxytetracycline.
Values were not significantly different among groups (p>0.05)
https://doi.org/10.1371/journal.pone.0229301.t003
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The development of an effective recombinant vaccine against A. marginale based on sub-
dominant antigens of the OM to block the host cells-parasite interplay requires further studies
to identify the critical epitopes of these antigens, express them as native proteins and deter-
mine the protein-protein interactions.
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